← Eichor
Condition: Chiauranib Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Chiauranib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Phase 3 · 1 location(s) · Chipscreen Biosciences, Ltd. · NCT04921527Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
Phase 1/Phase 2 · 11 location(s) · Chipscreen Biosciences, Ltd. · NCT05271292
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.